Orphan designation: satralizumab Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, 22/06/2026 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 24 August 2026 - 13:56

Orphan designation: satralizumab Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, 22/06/2026 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-26-3249

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters